Abnormal polyunsaturated lipid metabolism in the obese Zucker rat, with partial metabolic correction by gamma-linolenic acid administration.
Below-normal proportions of phospholipid (PL) arachidonic acid (20:4 omega 6) have been reported in serum from obese humans and in liver from obese Zucker rats. This implies an abnormality of 20:4 omega 6 formation from linoleic acid (18:2 omega 6), possibly in the delta 6 desaturase step, or alternatively an abnormality in the catabolism or distribution of arachidonate. We previously speculated that a reduced proportion of 20:4 omega 6 in hepatic PL could contribute to the etiology of genetic obesity. Providing 18:3 omega 6 would bypass delta 6 desaturase and possibly normalize hepatic PL 20:4 omega 6. Therefore weanling Zucker rats were given free access to a defined diet (11% of energy as soy oil) and gavaged daily with 100 microL of either black currant oil concentrate ([BCO] 8% 18:2 omega 6 and 70% 18:3 omega 6) or soy oil ([Soy] 55% 18:2 omega 6 and < 0.1% 18:3 omega 6). Groups of eight lean and eight obese animals were randomized to receive Soy or BCO in a 2 x 2 design; 10 obese and 10 lean rats were fed a stock diet (nongavaged reference). All groups of lean rats had identical weight gain; food intake for Soy lean and BCO lean did not differ. The obese reference animals and Soy obese animals did not differ in weight gain. However, BCO obese animals ate less food (P < .06), gained less weight (P < .0001), and had lower percent body fat (P < .05) compared with the Soy obese animals. The fatty acid constituents from serum, liver, and adipose tissue showed marked differences between lean and obese animals. Hepatic PL 20:4 omega 6 was lower in Soy obese than in lean (P < .002), but was normalized by BCO gavage (diet effect, P < .007). The paucity of hepatic PL 20:4 omega 6 was not due to reduced desaturase activity, as the proportions of other desaturase products (20:3 omega 6, 20:3 omega 9, 20:5 omega 3) were significantly elevated in Soy obese rat liver and serum. Serum and hepatic cholesteryl ester 20:4 omega 6 levels were elevated in obese versus lean rats (P < .02 and P < .0001), indicating abnormal arachidonate distribution in the obese Zucker rat. Because BCO selectively reduced weight gain and percent body fat in obese Zucker rats, our results imply a role for abnormal omega 6 fatty acid metabolism in the etiology of Zucker obesity.(ABSTRACT TRUNCATED AT 400 WORDS)
Phinney
S D
SD
Department of Internal Medicine, University of California at Davis.
Tang
A B
AB
Thurmond
D C
DC
Nakamura
M T
MT
Stern
J S
JS
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D004042:Dietary Fats, Unsaturated / Q000378:metabolism* / Q000494:pharmacology; D005228:Fatty Acids, Essential / Q000378:metabolism; D005838:Genotype; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009765:Obesity / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D011924:Rats, Zucker; D012016:Reference Values; D014280:Triglycerides / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects; D017965:gamma-Linolenic Acid / Q000494:pharmacology*
D004042:Dietary Fats, Unsaturated; D005228:Fatty Acids, Essential; D014280:Triglycerides; D017965:gamma-Linolenic Acid